3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome

Expert Review of Clinical Immunology

Volumn 6, Issue 6, 2010, Pages 867-874

  Wirtz, Paul W ^a   Titulaer, Maarten J ^b   Van Gerven, Joop M A ^b,c   Verschuuren, Jan J ^b  

^a HAGA HOSPITAL   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

3,4 diaminopyridine; clinical trials; Lambert Eaton myasthenic syndrome; neuromuscular diseases

Indexed keywords

3,4 DIAMINOPYRIDINE; MITOXANTRONE; PLACEBO; PYRIDOSTIGMINE; THEOPHYLLINE;

ABDOMINAL PAIN; ACRAL PARESTHESIA; ACUTE RESPIRATORY FAILURE; ASTHMA; CLINICAL TRIAL; DIGITAL PARESTHESIA; DISTRESS SYNDROME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EATON LAMBERT SYNDROME; ELECTROENCEPHALOGRAM; EPIGASTRIC DISTRESS; EPIPHORA; FATIGUE; HEART ARREST; HEART ARRHYTHMIA; HEART INFARCTION; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HEPATITIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSOMNIA; LIMB PAIN; MUSCLE ACTION POTENTIAL; MUSCLE ISOMETRIC CONTRACTION; MUSCLE STRENGTH; MUSCLE WEAKNESS; NAUSEA AND VOMITING; NONHUMAN; ORAL PARESTHESIA; OUTCOME ASSESSMENT; PARESTHESIA; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; POLLAKISURIA; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SLEEP DISORDER; TREATMENT DURATION;

4-AMINOPYRIDINE; ACTION POTENTIALS; CALCIUM CHANNELS; CHOLINERGIC AGENTS; CLINICAL PROTOCOLS; EPILEPSY; HUMANS; LAMBERT-EATON MYASTHENIC SYNDROME; MUSCLES; PARESTHESIA; PRESYNAPTIC TERMINALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78049450594     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.57     Document Type: Review

References (50)

1. Lambert EH, Eaton LM, Rooke ED. Defect of neuromuscular conduction associated with malignant neoplasms. Am. J. Physiol. 187, 612-613 (1956).
2. O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 111, 577-596 (1988).
3. Wirtz PW, Wintzen AR, Verschuuren JJ. Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer. Muscle Nerve 32, 226-229 (2005).
4. Titulaer MJ, Wirtz PW, Kuks JB et al. The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. J. Neuroimmunol. 15, 201-202 (2008).
5. Lang B, Newsom-Davis J, Wray D, Vincent A, Murray N. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 2, 224-226 (1981).
6. Prior C, Lang B, Wray D, Newsom-Davis J. Action of Lambert-Eaton myasthenic syndrome IgG at mouse motor nerve terminals. Ann. Neurol. 17, 587-592 (1985).
7. Pinto A, Iwasa K, Newland C, Newsom-Davis J, Lang B. The action of Lambert-Eaton myasthenic syndrome immunoglobulin G on cloned human voltage-gated calcium channels. Muscle Nerve 25, 715-724 (2002)
8. AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. Practice parameter for repetitive nerve stimulation and single fber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement. Muscle Nerve 24, 1236-1238 (2001).
9. Odabasi Z, Demirci M, Kim DS et al. Postexercise facilitation of refexes is not common in Lambert-Eaton myasthenic syndrome. Neurology 59, 1085-1087 (2002).
10. Wirtz PW, van Dijk JG, van Doorn PA et al. The epidemiology of the Lambert-Eaton myasthenic syndrome in The Netherlands. Neurology 63, 397-398 (2004).
11. Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome: electrodiagnostic fndings and response to treatment. Neurology 54, 2176-2178 (2000).
12. Nakao YK, Motomura M, Fukudome T et al. Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 59, 1773-1775 (2002).
13. Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J. Clin. Oncol. 26, 4276-4281 (2008).
14. Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 353, 117-118 (1999).
15. Willcox N, Demaine AG, Newsom-Davis J, Welsh KI, Robb SA, Spiro SG. Increased frequency of IgG heavy chain marker Glm(2) and of HLA-B8 in Lambert-Eaton myasthenic syndrome with and without associated lung carcinoma. Hum. Immunol. 14, 29-36 (1985).
16. Wirtz PW, Roep BO, Schreuder GM et al. HLA class I and II in Lambert-Eaton myasthenic syndrome without associated tumor. Hum. Immunol. 62, 809-813 (2001).
17. Wirtz PW, Willcox N, van der Slik AR et al. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J. Neuroimmunol. 159, 230-237 (2005).
18. Clamon GH, Evans WK, Shepherd FA, Humphrey JG. Myasthenic syndrome and small cell cancer of the lung. Variable response to antineoplastic therapy. Arch. Intern. Med. 144, 999-1000 (1984).
19. Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 40, 1552-1556 (1990).
20. Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 34, 480-485 (1984).
21. Bain PG, Motomura M, Newsom-Davis J et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 47, 678-683 (1996).
22. Dau PC, Denys EH. Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome. Ann. Neurol. 11, 570-575 (1982).
23. Lambert EH. Defects of neuromuscular transmission in syndromes other than myasthenia gravis. Ann. NY Acad. Sci. 135, 367-384 (1966).
24. Murray NM, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 31, 265-271 (1981).
25. McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N. Engl. J. Med. 321, 1567-1571 (1989).
26. Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 54, 603-607 (2000).
27. Wirtz PW, Verschuuren JJ, van Dijk JG et al. Effcacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin. Pharmacol. Ther. 86, 44-48 (2009).
28. Oh SJ, Claussen GG, Hatanaka Y, Morgan MB. 3,4-diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve 40, 795-800 (2009).
29. Murray NMF, Newsom-Davis J, Karni Y, Wiles CM. Oral 3,4-diaminopyridine in the treatment of the Lambert-Eaton myasthenic syndrome (LEMS) [abstract]. J. Neurol. Neurosurg. Psychiatry 47, 1052 (1984).
30. Molgó J, Lundh H, Thesleff S. Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur. J. Pharmacol. 61, 25-34 (1980).
31. Thomsen RH, Wilson DF. Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction. J. Pharmacol. Exp. Ther. 227, 260-265 (1983).
32. Kirsch GE, Narahashi T 3,4-diaminopyridine. A potent new potassium channel blocker. Biophys. J. 22, 507-512 (1978).
33. Lemeignan M, Millart H, Lamiable D, Molgó J, Lechat P. Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fuid in anesthetized rats. Brain Res. 304, 166-169 (1984).
34. Lundh H, Nilsson O, Rosén I. Novel drug of choice in Eaton-Lambert syndrome. J. Neurol. Neurosurg. Psychiatry 46, 684-685 (1983).
35. Solari A, Uitdehaag B, Giuliani G, Pucci E, Taus C. Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst. Rev. 2, CD001330 (2003).
36. Vohra MM, Pradhan SN. Pharmacology of 3,4-diaminopyridine. Arch. Int. Pharmacodyn. Ther. 150, 413-424 (1964).
37. Lechat P, Deysson G, Lemeignan M, Adolphe M. [Toxicité aiguë composée de quelques aminopyridines in vivo (souris) et in vitro (cultures cellulaires)]. Ann. Pharm. Fr. 26, 345-349 (1968).
38. Durant NN, Marshall IG. The effects of 3,4-diaminopyridine on spontaneous and evoked transmitter release at the frog neuromuscular junction (proceedings). J. Physiol. 280, 21P (1978).
39. Bever CT Jr, Leslie J, Camenga DL, Panitch HS, Johnson KP. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis. Ann. Neurol. 27, 421-427 (1990).
40. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW Reliability testing of the quantitative myasthenia gravis score. Ann. NY Acad. Sci. 841, 769-772 (1998).
41. Sanders DB. 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Ann. NY Acad. Sci. 841, 811-816 (1998).
42. Lundh H, Nilsson O, Rosén I. Treatment of Lambert-Eaton myasthenic syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology 34, 1324-1330 (1984).
43. Boerma CE., Rommes JH., van Leeuwen RB, Bakker J. Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome. J. Toxicol. Clin. Toxicol. 33, 249-251 (1995).
44. Lundh H, Nilsson O, Rosén I, Johansson S. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome. Acta Neurol. Scand. 88, 136-140 (1993).
45. Bever CT Jr, Anderson PA, Leslie J et al. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 47, 1457-1462 (1996).
46. Flet L, Polard E, Guillard O et al. 3,4-Diaminopyridine safety in clinical practice: an observational, retrospective cohort study J. Neurol. 57, 937-946 (2010).
47. Skeie GO, Apostolski S, Evoli A et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders (EFNS Task Force article). Eur. J. Neurol. 13, 691-699 (2006).
48. European Medicines Agency Committee for Orphan Medicinal Products. Public summary of opinion on orphan designation. 3,4 diaminopyridine phosphate for the treatment of Lambert-Eaton myasthenic syndrome. EMA/COMP/2732/2002 Rev.3. EMA, London, UK (2010).
49. Pellkofer HL, Voltz R, Kuempfel T. Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction. Muscle Nerve 40, 305-308 (2009).
50. Maddison P, McConville J, Farrugia ME et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J. Neurol. Neurosurg. Psychiatry DOI: jnnp.2009.197632 (2010) (Epub ahead of print).